GleamWall
中文EN

TNYA Tenaya Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1858848 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-8.0%
TTM EPS YoY36.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-148.2%
ROA-112.1%
ROIC (approx.)-1,156.6%
Asset turnover—

Leverage & solvency

Liabilities / assets28.9%
Debt / equity0.00x
Current ratio3.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.53x
Accruals ratio-52.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.70M$1.11M$225,000——$0$0—
R&D expense$14.87M$16.60M$14.84M$14.80M$15.36M$17.37M$21.08M$18.69M
SG&A expense$5.65M$5.41M$5.45M$5.98M$5.57M$6.71M$6.46M$5.96M
Operating income-$19.57M-$44.09M-$20.07M-$20.77M-$20.94M-$24.08M-$27.54M-$24.65M
Pretax income-$18.94M-$43.39M-$19.27M-$20.18M-$20.27M-$23.28M-$26.86M-$23.84M
Income tax$0$0$0$0$0$0$0$0
Net income-$18.94M-$43.39M-$19.27M-$20.18M-$20.27M-$23.28M-$26.86M-$23.84M
EBITDA-$19.17M-$42.39M-$18.30M-$18.95M-$19.04M-$21.98M-$24.88M-$22.56M
EPS (basic)-0.08-0.20-0.09—-0.12-0.14-0.24—
EPS (diluted)-0.08-0.20-0.09—-0.12-0.14-0.24—
Weighted avg. shares (diluted)226.01M217.57M216.88M—163.35M162.79M109.87M—
Balance sheet
Cash & equivalents$66.80M$78.08M$80.89M$100.55M$56.31M$62.67M$53.77M$4.32M
Short-term investments—————$9.00M$34.39M$57.12M
Receivables$573,000$371,000$10.63M—————
Current assets$71.01M$86.01M$96.56M$105.59M$61.24M$75.88M$94.48M$67.38M
PP&E, net$1.14M$2.49M$25.96M$27.67M$29.44M$31.29M$33.36M$35.86M
Total assets$76.68M$93.54M$135.07M$146.92M$104.98M$122.15M$143.95M$119.94M
Current liabilities$18.80M$19.02M$16.78M$15.44M$13.21M$12.65M$14.15M$15.97M
Total liabilities$22.16M$24.13M$28.88M$23.66M$22.11M$22.32M$24.56M$27.09M
Shareholders' equity$54.52M$69.41M$106.19M$123.27M$82.87M$99.83M$119.40M$92.85M
Shares outstanding227.93M224.23M217.00M216.76M———86.54M
Cash flow statement
Operating cash flow-$17.68M-$3.55M-$19.23M-$13.94M-$15.60M-$15.61M-$23.11M-$18.39M
Capital expenditure$0$159,000$11,000$67,000$26,000$142,000$383,000$204,000
Free cash flow-$17.68M-$3.71M-$19.25M-$14.01M-$15.62M-$15.76M-$23.50M-$18.59M
Investing cash flow$26,000-$159,000-$11,000-$67,000$8.86M$24.99M$22.30M$14.10M
Financing cash flow$6.37M$909,000-$415,000$58.24M$380,000-$476,000$50.26M$377,000
Depreciation & amortization$400,000$1.70M$1.76M$1.83M$1.90M$2.10M$2.66M$2.09M
Stock-based compensation$1.68M$1.70M$2.20M$2.75M$2.93M$3.63M$3.63M$3.76M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.